Meeting
2021 ASCO Annual Meeting
Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
Authors
Omid Hamid
The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA
Omid Hamid , Ding Wang , Tae Min Kim , Sang-We Kim , Nehal J. Lakhani , Melissa Lynne Johnson , Roman Groisberg , Kyriakos P. Papadopoulos , John M. Kaczmar , Mark R. Middleton , Alexander I. Spira , Stephen K. Williamson , Guilherme Rabinowits , Rodolfo Gutierrez , Meredith McKean , Shuquan Chen , James Cassidy , Jayakumar Mani , Tasha Nicholle Sims , Glenn Kroog
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03005782
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9515)
DOI
10.1200/JCO.2021.39.15_suppl.9515
Abstract #
9515
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2024 ASCO Annual Meeting
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.
First Author: Nikhil I. Khushalani
Poster
2023 ASCO Annual Meeting
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.
First Author: Inderjit Mehmi
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.
First Author: Kyriakos P. Papadopoulos